Compare SWKS & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWKS | DVA |
|---|---|---|
| Founded | 1962 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Misc Health and Biotechnology Services |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 10.0B |
| IPO Year | 1995 | 2002 |
| Metric | SWKS | DVA |
|---|---|---|
| Price | $57.19 | $149.55 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 15 | 4 |
| Target Price | $72.85 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 2.7M | 644.6K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.03% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.53 | ★ 9.84 |
| Revenue | $4,086,900,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | N/A | $3.85 |
| Revenue Next Year | $3.06 | $3.07 |
| P/E Ratio | $106.53 | ★ $15.43 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $51.93 | $101.00 |
| 52 Week High | $90.90 | $159.42 |
| Indicator | SWKS | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 56.40 | 49.72 |
| Support Level | $56.52 | $145.62 |
| Resistance Level | $61.80 | $152.31 |
| Average True Range (ATR) | 1.72 | 3.56 |
| MACD | 0.47 | -0.65 |
| Stochastic Oscillator | 92.68 | 38.57 |
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.